Trial Profile
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Sutimlimab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CARDINAL
- Sponsors Bioverativ
- 12 Dec 2023 Results of Post-Hoc Analysis Part A and B of the Phase 3 Cardinal(n=24) and Cadenza(n=42), presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results determining the cost-effectiveness of sutimlimab versus standard-of-care for the transfusion-dependent patient population with primary CAD, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 01 Aug 2023 Results published in the American Journal of Hematology